Milford, MA – According to filings with the U.S. Securities and Exchange Commission, Reprieve Cardiovascular is raising $15,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Mark Pacyna played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Reprieve Cardiovascular
Reprieve Cardiovascular is led by a seasoned management team with extensive experience in the medical device industry. Reprieve Cardiovascular is a developer of an acute decompensated heart failure (ADHF) treatment medical device intended to help patients experience life without limits. The company’s medical devices offer a proprietary method of diuretic therapy that enables precise and predictable management of a patients fluid levels, guarding against dangerous fluid imbalances and controls over diuretic therapy, enabling medical practitioners to ensure a better quality of life for the patient.

To learn more about Reprieve Cardiovascular, visit http://reprievecardio.com/

Contact:
Mark Pacyna, Chief Executive Officer
650-388-3676
https://www.linkedin.com/in/mark-pacyna-3b5135/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved